Skip to main content
Smart Investors Daily
NexImmune, Inc. logo

OTC · NEXI

NexImmune, Inc.

Healthcare · Biotechnology

$0.00

Up+$0.00 (+0.00%)

Updated Aug 23, 2026, 7:57 PM

SID Score

3.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
139
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.00 – $1.01
Volume
178
Avg. volume
496

Price performance

NEXI price history

1M range · 2 trading sessions · Daily adjusted prices

NEXI closed at $0.00 after 2 trading sessions, up 0.00% for the selected period.

Last close
$0.00
Period change
+0.00%
Period low
$0.00
Period high
$0.00
Daily close
View OHLC price history
NEXI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 19, 2026$0.0001$0.0001$0.0001$0.0001178
Aug 14, 2026$0.0001$0.0001$0.0001$0.0001132

Latest NEXI news

The latest Smart Investors Daily articles mentioning NEXI.

NEXI research

Overview

Company profile and research snapshot.

Company profile

NEXIMMUNE INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$3.33
Implied upside
Analysts
NEXI recent ratings
DateFirmRatingTarget
Nov 16, 2022Cantor FitzgeraldNeutral
Nov 15, 2022Raymond JamesMarket Perform
Aug 16, 2022Raymond JamesOutperform
Aug 16, 2022BarclaysOverweight
Jun 1, 2022BTIGBuy
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Dec 10, 2025

Critical Comparison: NexImmune (NASDAQ:NEXI) vs. IMV (OTCMKTS:IMVIQ)

Earnings and Valuation This table compares NexImmune and IMV"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A IMV $330,000.00 0.00 -$37.99 million ($4.59) N/A NexImmune has higher earnings, but lower revenue than IMV. Risk and Volatility NexImmune has

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.